CoChat

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Summary: Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) axis plays a key role in immunosuppressive properties of the tumor microenvironment, patient prognosis, and chemoresistance. This phase Ib study assessed the effects of the orally administered CCR2 inhibitor PF-04136309 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic PDAC. Methods Patients received PF-04136309 twice daily (BID) continuously plus nab-paclitaxel (125 mg/m 2 ) and gemcitabine (1000 mg/m 2 ) administered on days 1, 8, and 15 of each 28-day cycle. The primary objectives were to evaluate safety and tolerability, characterize dose-limiting toxicities (DLTs), and determine the recommended phase II dose (RP2D) of PF-04136309. Results In all, 21 patients received PF-04136309 at a starting dose of 500 mg or 750 mg BID. The RP2D was identified to be 500 mg BID. Of 17 patients treated at the 500 mg BID starting dose, three (17.6%) experienced a total of four DLTs, including grade 3 dysesthesia, diarrhea, and hypokalemia and one event of grade 4 hypoxia. Relative to the small number of patients (n = 21), a high incidence (24%) of pulmonary toxicity was observed in this study. The objective response rate for 21 patients was 23.8% (95% confidence interval: 8.2–47.2%). Levels of CD14 + CCR2+ inflammatory monocytes (IM) decreased in the peripheral blood, but did not accumulate in the bone marrow. Conclusions PF-04136309 in combination with nab-paclitaxel plus gemcitabine had a safety profile that raises concern for synergistic pulmonary toxicity and did not show an efficacy signal above nab-paclitaxel and gemcitabine. ClinicalTrials.gov identifier: NCT02732938.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-019-00830-3

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clinical response. a Bar plot for duration of treatment by dose level (including response, dose reduction, and DLT). mITT population was analyzed. Only the first time of dose reduction is presented. Each bar represents one patient in the study. Duration was calculated as follows: (last dose date – first dose date +1) / 7. b Waterfall plot of tumor size percent change data. mITT population was analyzed. Largest decrease or smallest increase represents best response to treatment. Only patients with target lesions at baseline and at least one post-baseline target lesion based on investigator assessment per RECIST version 1.1 are included (n = 18). Abbreviations: BID twice daily, DLT dose-limiting toxicity, DR dose reduction, In indeterminate, mITT modified intent-to-treat, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable/no response, Un PR unconfirmed partial response
Fig. 1 Clinical response. a Bar plot for duration of treatment by dose level (including response, dose reduction, and DLT). mITT population was analyzed. Only the first time of dose reduction is presented. Each bar represents one patient in the study. Duration was calculated as follows: (last dose date – first dose date +1) / 7. b Waterfall plot of tumor size percent change data. mITT population was analyzed. Largest decrease or smallest increase represents best response to treatment. Only patients with target lesions at baseline and at least one post-baseline target lesion based on investigator assessment per RECIST version 1.1 are included (n = 18). Abbreviations: BID twice daily, DLT dose-limiting toxicity, DR dose reduction, In indeterminate, mITT modified intent-to-treat, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable/no response, Un PR unconfirmed partial responseCC BY · PubMed Central
Fig. 2 Effect of PF-04136309 in combination with nab-paclitaxel/gemcitabine on the CCL2 pathway. a and b Plasma CCL2 levels of individuals were examined by an immunoassay using a luminex-based method. c and d Individual plots of CCL2-induced pERK by treatment group. Target engagement was measured by an ex vivo CCL2-induced pERK assay. a and c treatment group: 750 mg BID PF-04136309 + nab-paclitaxel/gemcitabine. b and d treatment group: 500 mg BID PF-04136309 + nab-paclitaxel/gemcitabine. Each symbol represents individual patient. Abbreviations: BID twice daily, C cycle, CCL2 the chemokine (C-C motif) ligand 2, D day, EOT end of treatment, Fl fluorescence intensity, F-U follow-up, H hour, nab-P/gem nab-paclitaxel/gemcitabine, pERK phosphorylated extracellular signal regulated kinase phosphorylation, PRE before treatment
Fig. 2 Effect of PF-04136309 in combination with nab-paclitaxel/gemcitabine on the CCL2 pathway. a and b Plasma CCL2 levels of individuals were examined by an immunoassay using a luminex-based method. c and d Individual plots of CCL2-induced pERK by treatment group. Target engagement was measured by an ex vivo CCL2-induced pERK assay. a and c treatment group: 750 mg BID PF-04136309 + nab-paclitaxel/gemcitabine. b and d treatment group: 500 mg BID PF-04136309 + nab-paclitaxel/gemcitabine. Each symbol represents individual patient. Abbreviations: BID twice daily, C cycle, CCL2 the chemokine (C-C motif) ligand 2, D day, EOT end of treatment, Fl fluorescence intensity, F-U follow-up, H hour, nab-P/gem nab-paclitaxel/gemcitabine, pERK phosphorylated extracellular signal regulated kinase phosphorylation, PRE before treatmentCC BY · PubMed Central
Fig. 3 Changes of immune cell levels in the peripheral blood, bone marrow, or tumor after dosing with PF-04136309 in combination with nab-paclitaxel/gemcitabine. Changes of CD14+ CCR2+ monocytes in patients with (a) best response of stable disease or partial response or (b) patients with progressive disease, serious adverse event, or withdrawn from study. c Percentage change of CCR2+ monocytes in the bone marrow. Bar represents SEM. d Percentage of CD8+, CD4+, and CD4 + FoxP3+ T cells in biopsy samples at baseline and week 6. Each symbol represents individual patient. Abbreviations: AE adverse event, CCR2 chemokine (C-C motif) receptor 2, EOT end of treatment, nab-P/gem nab-paclitaxel/gemcitabine, SEM standard error of mean; Treg regulatory T cell
Fig. 3 Changes of immune cell levels in the peripheral blood, bone marrow, or tumor after dosing with PF-04136309 in combination with nab-paclitaxel/gemcitabine. Changes of CD14+ CCR2+ monocytes in patients with (a) best response of stable disease or partial response or (b) patients with progressive disease, serious adverse event, or withdrawn from study. c Percentage change of CCR2+ monocytes in the bone marrow. Bar represents SEM. d Percentage of CD8+, CD4+, and CD4 + FoxP3+ T cells in biopsy samples at baseline and week 6. Each symbol represents individual patient. Abbreviations: AE adverse event, CCR2 chemokine (C-C motif) receptor 2, EOT end of treatment, nab-P/gem nab-paclitaxel/gemcitabine, SEM standard error of mean; Treg regulatory T cellCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 228

Metadata

Authors
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., Yin, D., Joh, T., Jacobs, I. A., Taylor, C. T., & Lowery, M. A.
Affiliations
  • University of Rochester Medicine (US)
  • Dana-Farber Cancer Institute (US)
  • Massachusetts General Hospital (US)
  • Beth Israel Deaconess Medical Center (US)
  • Medical University of South Carolina (US)
  • Pfizer (United States) (US)
  • Trinity College Dublin (IE)
Corresponding author
Jacobs, Ira A.
Venue
Investigational New Drugs
Published
2019-07-12
Volume
38
Issue
3
Pages
800-811
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2959661609
Cited by
199
References
30
Citations by year
2026: 36 · 2025: 25 · 2024: 33 · 2023: 31 · 2022: 26 · 2021: 28 · 2020: 18 · 2019: 1
FWCI
7.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Investigational New Drugs (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
CCR2 inhibitor, CCL2/CCR2 axis, metastatic pancreatic ductal adenocarcinoma, nab-paclitaxel, gemcitabine, first-line therapy, pulmonary toxicity, inflammatory monocytes, dose-limiting toxicity, recommended phase 2 dose
MeSH terms
Gemcitabine, Adenocarcinoma, Aged, Albumins, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Pyrrolidines, Cohort Studies, Paclitaxel, Chemokine CCL2, Carcinoma, Pancreatic Ductal, Small Molecule Libraries, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.